OT 0 8 2004 W

PATENT Docket No. 180.0005 0102

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):	Sandor LOVAS et al.)	Group Art Unit:	1653
Serial No.: Confirmation)	Examiner:	Unassigned
Filed:	28 October 2003)		

For:

NOVEL GnRH ANALOGUES WITH ANTITUMOUR EFFECTS AND

PHARMACEUTICAL COMPOSITIONS THEREOF

FACSIMILE TRANSMISSION TO THE PTO

Mail Stop Missing Parts

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

FAX NUMBER: 703) 746-4060

Total Pages (including cover page): 5

Time: 10:00M (Central Time)

(Transmission must be complete by midnight eastern time.)

The following papers are being transmitted to the Patent and Trademark Office by facsimile transmission:

- X Response to Notice to Comply with Requirements for Patent Applications
 Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (2 pgs)
- X Copy of "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" (2 pg)
- X Small Entity Status is entitled to be asserted in the above-identified application.

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers and please charge any additional fees or credit overpayment to Deposit Account No. 13-4895.

Mueting, Raasch & Gebhardt, P.A.

Customer Number: 26813

By: MM Mueting

Ann M. Mueting

Reg. No. 33,977

Direct Dial (612)305-1217

CERTIFICATE UNDER 37 C.F.R. §1.8: The undersigned hereby certifies that this Facsimile Cover Sheet and the paper(s), as described hereinabove, are being transmitted by facsimile in accordance with 37 CFR §1.6(d) to the Patent and Trademark Office addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 3 day of October, 2004, at 10.104M (Central Time).

8 OCTOBER 2004

Printed Name: Kerly J. McNeutry

If you do not receive all pages, please contact us at (612)305-1220 (ph) or (612)305-1228 (fax),



PATENT Docket No. 180.0005 0102

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s).	Saidor LOVAS et al.) (Group Art Unit: 1653		
Serial No.: Confirm. No.:	10/695,382 5299)))	Examiner:	Unassigned	
Filed:	28 October 2003)			
For:	NOVEL GnRH ANALOGUI PHARMACEUTICAL COM	ES WITH POSITIC	I ANTITUMO	OUR EFFECTS AND	

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Mail Stop Missing Parts Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Applicants are in receipt of the "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" mailed 10 August 2004 from the OIPE division of the U.S. Patent and Trademark Office. Applicants believe this Notice was sent in error.

In consideration that Applicants previously received a "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" (mailed 02 February 2004) and, in response, Applicants filed a Preliminary Amendment with a Request for Transfer of Computer Readable Form of Sequence Listing on 02 April 2004, Applicants were unclear why a second "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" was mailed on 10 August 2004.

Page 2 of 2

esponse to Notice to Comply with Requirements...

Applicant(s):

Sandor LOVAS et al.

Serial No.:

10/695,382

Filed:

28 October 2003

For:

NOVEL GORH ANALOGUES WITH ANTITUMOUR EFFECTS AND PHARMACEUTICAL

COMPOSITIONS THEREOF

Applicants' Representatives contacted Ms. Anne-Marie Corrigan (ph: 571-272-2501) of the STIC System Branch for further clarification. Ms. Corrigan reviewed the case and found that, on 18 May 2004, the OIPE sent the STIC division a transfer statement that authorized the transfer of the sequence listing from the parent case (U.S. Serial No. 09/269,954; issued as U.S. Patent No. 6,664,369 B1 on 16 December 2003) to the instant application. This authorization was processed on 19 May 2004 and there were no errors reported in the Sequence Listing.

In consideration thereof, Ms. Corrigan confirmed that the "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" mailed 10 August 2004 was sent in error and no further response is necessary.

Please contact the undersigned attorney with any questions regarding this matter.

CERTIFICATE UNDER 37 C.F.R. 1.8:

The undersigned hereby certifies that this Facsimile Cover Sheet and the paper(s), as described hereinabove, are being transmitted by facsimile in accordance with 37 CFR §1.6(d) to the Patent and Trademark Office addressed to Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this _______ day of APRIL 2004, at

(Central Time)

Signature:____ Printed Name

By Mueting, Raasch & Gebhardt, P.A.

P.O. Box 581415

LOVAS et al.

Minneapolis, MN 55458-1415

Telephone (612)305-1220

Respectfully submitted for

Facsimile (612)305-1228

Customer Number 26813

Date

AMM/kjm

Ann M. Mueting

Reg. No. 33,977

Direct Dial (612)305-1217



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United Statum Pateus and Tradesaurk Office Address: COMMISSIONER FOR PATENTS Box 1419 Alexandria, Viginia 22313-1450

APPLICATION NUMBER

FILING OR 371 (c) DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

10/695,382

10/28/2003

Sandor Lovas

180.0005 0102

26813 MUETING, RAASCH & GEBHARDT, P.A. P.O. BOX 581415 MINNEAPOLIS, MN 55458 CONFIRMATION NO. 5299
FORMALITIES LETTER
IMPLIANTIAL HOLD TO THE TOTAL TO THE TOTAL

Date Mailed: 08/10/2004

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Filing Date Granted

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c) Applicant must provide an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Replies should be mailed to:

Mail Stop Missing Parts

Commissioner for Patents

P.O. Box 1450

Alexandria VA 22313-1450

A copy of this notice MUST be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE